{"disease":{"id":"unresectable-or-metastatic-melanoma","name":"Unresectable or metastatic melanoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"cobimetinib","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cotellic","generic_name":"cobimetinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells."},{"drug_id":"mek162","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mektovi","generic_name":"mek162","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 1","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth."},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"lifileucel","indication_name":"Unresectable or Metastatic Melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LIFILEUCEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"relatlimab-rmbw","indication_name":"Unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"opdualag","indication_name":"Unresectable or metastatic melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01844505","title":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT01721746","title":"A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT04653038","title":"A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT04768881","title":"Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Karyopharm Therapeutics Inc","has_results":true},{"nct_id":"NCT01826448","title":"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT01810016","title":"NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Ludwig Institute for Cancer Research","has_results":true},{"nct_id":"NCT05003622","title":"Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":true},{"nct_id":"NCT03993379","title":"PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"CytomX Therapeutics","has_results":true},{"nct_id":"NCT06984328","title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Genmab","has_results":false}],"total":11},"guidelines":[{"drug_id":"cobimetinib","guideline_body":"FDA label","recommendation":"COTELLIC® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}